Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.61 |
| ▸ | JAK1 | P23458 | 8/20 | 0.60 |
| ▸ | JAK3 | P52333 | 6/20 | 0.60 |
| ▸ | TYK2 | P29597 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | LTK | P29376 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695723 | 0.86 | JAK2 (0.65) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL20908684 | 0.84 | JAK2 (0.69) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL13774665 | 0.84 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL101195 | 0.81 | JAK2 (0.62) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL28340692 | 0.81 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL101593 | 0.81 | JAK2 (0.62) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL27741963 | 0.81 | JAK2 (0.65) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL100975 | 0.81 | JAK2 (0.55) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL27741962 | 0.81 | JAK2 (0.56) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL2145069 | 0.80 | JAK2 (0.53) | JAK2HDAC6HDAC1JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-23 | — | — | US | disclosed |
| US-8741912-B2 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741912-B2 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-12-13 | — | — | US | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088445-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | JAK2 3/4885HDAC6 618/4885HDAC1 640/4885 |
| US-20140315931-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885HDAC6 618/4885HDAC1 640/4885 |
| US-20090227607-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885HDAC6 618/4885HDAC1 640/4885 |
| US-20120316186-A1 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | JAK2 3/4885HDAC6 618/4885HDAC1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.